Fed. Circ. Urged To Reconsider Enzo DNA Patent Case
Enzo Life Sciences Inc. has urged the Federal Circuit to reconsider its earlier decision invalidating a pair of DNA testing patents, arguing that a panel improperly relied on testimony to find...To view the full article, register now.
Already a subscriber? Click here to view full article